LA JOLLA, Calif., Dec. 15, 2015 /PRNewswire/ -- SGI-DNA, a Synthetic Genomics, Inc. (SGI) company, has launched a suite of Cell Engineering Services for generation of custom mammalian cell lines for research use. Cell lines developed using this service are appropriate for the expression of novel proteins as well as a variety of functional studies, including cell-based assays for compound screening.
The introduction of this service provides research laboratories access to all aspects of SGI's extensive cell engineering experience for design, development and generation of custom cell lines with novel properties. Unique to this service is the SGI Archetype® software which offers extensive genomic databases, proprietary algorithms, and bioinformatics tool sets to aid design.
For each project, SGI-DNA's scientific staff collaborates with clients and partners to provide expert insight and develop innovative strategies that leverage their advanced technologies. To ensure reliable data, cell lines developed by SGI-DNA are verified by sequencing and further validated upon customer request. This results in a fully-optimized cell engineering approach designed to alleviate challenges, such as variable protein expression, low product yields, and protein instability.
As part of the development of this service, experienced SGI-DNA scientists have applied their knowledge to a range of projects including:
"SGI's research efforts have greatly expanded our mammalian cell engineering capabilities. This has allowed us to develop innovative approaches to address extremely complex mammalian cell engineering challenges in our collaborations with leading biopharmaceutical partners," said Sean Stevens, SGI's leader of Mammalian Synthetic Biology. "Through SGI-DNA, we can now offer precise cell engineering services which take advantage of our unique combination of proprietary sequence databases, state of the art bioinformatics, and experimental know how."
Key advantages of SGI-DNA's Cell Engineering Service:
A key technology behind SGI-DNA's Cell Engineering Services is the Gibson Assembly® method, developed in 2009 by Dan Gibson and his colleagues at the J. Craig Venter Institute along with Synthetic Genomics. In 2010 this well-established approach was used to create the first fully synthetic cell. Since the commercial introduction of the Gibson Assembly® method to the life science community by SGI-DNA, this method has become a mainstay in many synthetic biology laboratories and has attracted interest from both the academic and commercial life sciences community due to its ease-of-use, robustness, and flexibility.
To request a quote or for more information, please visit www.sgidna.com/cellengineering
All products and services are intended for research use only. Not intended for diagnostic or therapeutic uses.
The Gibson Assembly® method is also available under commercial license. For more information contact us at [email protected]
About SGI-DNA
SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc (SGI), is responsible for all commercial aspects of SGI's synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Ham Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers the BioXp™ 3200 System, the world's first DNA printer, in addition to a comprehensive suite of genomic services, including whole genome sequencing, library design, bioinformatics services, and reagent kits to enable synthetic biology.
Logo - http://photos.prnewswire.com/prnh/20150901/262710LOGO
SOURCE SGI-DNA
Share this article